Colon Cancer Stages: TNM 8th Edition, Stage 0–IV Explained

• Colon cancer is staged using the AJCC/UICC TNM system, 8th edition. T = tumour depth, N = nodes, M = metastasis.
• The pathological stage (after surgery) is the one that drives adjuvant chemotherapy decisions, not the clinical stage from scans.
• At least 12 lymph nodes must be examined for a reliable N stage; fewer than 12 is a high-risk feature on its own.
• Stage groups run from 0 (cancer cells in the lining only) to IVC (peritoneal spread).
• Molecular markers (RAS, BRAF, MMR/MSI, HER2) do not change the stage, but shape drug choice once the stage is set.
• Surgery is the curative modality for Stage 0–III; VICI Healthcare daycare delivers the medical portion — adjuvant chemotherapy, targeted therapy, and immunotherapy infusions.

Stage is the single biggest number your oncologist will use to plan treatment. It answers three questions at once: how deep has the tumour grown into the bowel wall, whether any lymph nodes near the bowel contain cancer cells, and whether cancer has reached a distant organ such as the liver, lung, or peritoneum. Colon cancer uses the AJCC/UICC TNM 8th edition. T is for tumour depth, N is for nodes, M is for metastasis. Those three letters together place the disease into a stage group from 0 to IV [1][2].

Two things are worth knowing up front. First, the stage is set at diagnosis and does not change later. If you were diagnosed with Stage III and later develop a liver metastasis, that is called “Stage III with recurrence to liver”, not Stage IV. Second, the stage you get on imaging before surgery (clinical stage, written cT cN cM) can shift after the pathologist examines the surgical specimen (pathological stage, pT pN pM). The pathological stage is the one that drives adjuvant treatment decisions [1][3].

The Indian workflow usually runs like this. A colonoscopy with biopsies confirms adenocarcinoma. A contrast-enhanced CT of the chest, abdomen, and pelvis looks for depth of invasion, enlarged nodes, liver lesions, lung nodules, and peritoneal disease. Serum CEA is drawn as a baseline. In most Indian tertiary centres, MRI is reserved for rectal tumours and is not routine for colon. PET-CT is added when CT is equivocal, when CEA is rising without a visible site, or before a major liver resection. Molecular testing (RAS, BRAF, MMR/MSI, HER2) is done on the biopsy or the resected specimen and does not change the anatomical stage, but it shapes drug choice once the stage is set [3][4].

Staging in colon cancer is almost always finalised after surgery, because the pathologist has to count nodes. You need at least 12 lymph nodes examined for a reliable N stage. Fewer than 12 nodes is flagged as inadequate nodal yield and is, by itself, a reason some oncologists will recommend adjuvant chemotherapy for an otherwise low-risk tumour [5].

• Tis: carcinoma in situ, limited to the inner lining or just into the lamina propria. Does not metastasise.
• T1: tumour invades the submucosa.
• T2: tumour invades the muscularis propria.
• T3: tumour grows through the muscularis propria into the subserosa or non-peritonealised pericolic tissue.
• T4a: tumour penetrates the visceral peritoneum.
• T4b: tumour directly invades or is adherent to another organ (bladder, small bowel loop, abdominal wall).

• N0: no regional node metastasis.
• N1a: one regional node positive.
• N1b: two or three regional nodes positive.
• N1c: tumour deposits in the subserosa, mesentery, or non-peritonealised pericolic tissue without a positive node. Added in the 8th edition because tumour deposits predict outcome the way positive nodes do.
• N2a: four to six regional nodes positive.
• N2b: seven or more regional nodes positive.

• M0: no distant spread.
• M1a: metastasis confined to one organ or site (liver, lung, ovary, non-regional node) without peritoneal involvement.
• M1b: metastasis in two or more organs or sites without peritoneal involvement.
• M1c: peritoneal metastasis, with or without other organ involvement. Peritoneal disease was separated in the 8th edition because its prognosis and treatment path (cytoreductive surgery and, in selected cases, HIPEC) are different [1][2].

Stage 0 is usually removed at the time of colonoscopy by endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD). If the margins are clean and there is no lymphovascular invasion, no further treatment is needed. A surveillance colonoscopy is scheduled. Chemotherapy has no role here. The goal at this stage is clean excision and long-term endoscopic follow-up.

Surgery alone is curative for most Stage I colon cancers. The standard operation is a segmental colectomy with a complete mesocolic excision and an adequate lymphadenectomy (at least 12 nodes). Adjuvant chemotherapy is not routine. Surveillance follows the Stage III template but at a lower intensity.

Stage II is the stage where decisions split. Surgery comes first. The question is whether adjuvant chemotherapy adds enough benefit to be worth the toxicity. We look for high-risk features: T4 tumour, inadequate nodal yield (<12 nodes), lymphovascular or perineural invasion, poorly differentiated histology (except MSI-high), obstruction or perforation at presentation, and elevated post-operative CEA. For high-risk Stage II, a fluoropyrimidine-based regimen (capecitabine alone, or CAPOX/FOLFOX) is commonly offered for three to six months. For Stage II disease that tests MSI-high, single-agent fluoropyrimidine is generally avoided because the benefit is small; immunotherapy is reserved for metastatic disease or specific trial contexts [4][5].

Stage III is the classic adjuvant chemotherapy stage. Surgery with complete mesocolic excision is followed by oxaliplatin-based adjuvant chemotherapy: CAPOX (capecitabine plus oxaliplatin) or FOLFOX (5-FU, leucovorin, and oxaliplatin). The IDEA collaboration showed that three months of CAPOX is a reasonable option for lower-risk Stage III (T1–T3, N1), while six months remains the standard for higher-risk Stage III (T4 or N2). The main trade-off is oxaliplatin-induced peripheral neuropathy, which is dose-dependent and partly reversible [8].

Stage IV treatment is individualised, and the central question is whether the metastases are resectable. Three broad pathways exist.

Oligometastatic, resectable disease. A small number of liver or lung metastases that a surgeon can clear. Perioperative chemotherapy (commonly FOLFOX with or without bevacizumab, or FOLFOXIRI in fit patients) plus metastasectomy gives long-term survival in a meaningful subset.

Metastatic, unresectable but treatable. Systemic therapy chosen on molecular testing. RAS wild-type left-sided tumours go to doublet chemotherapy plus an anti-EGFR antibody (cetuximab or panitumumab). RAS mutant or right-sided tumours go to doublet with or without bevacizumab. BRAF V600E mutant disease moves to encorafenib plus cetuximab after first-line. MSI-high disease gets pembrolizumab or nivolumab with or without ipilimumab as first-line, based on KEYNOTE-177 and CheckMate 8HW. HER2-amplified, RAS/BRAF wild-type disease is treated with trastuzumab plus tucatinib, trastuzumab with pertuzumab, or trastuzumab deruxtecan in later lines. KRAS G12C gets sotorasib or adagrasib combined with cetuximab in later lines. NTRK fusion-positive disease responds to larotrectinib or entrectinib. Later lines include trifluridine–tipiracil (TAS-102) with or without bevacizumab, regorafenib, and fruquintinib [4][9].

Peritoneal disease (M1c). Selected fit patients with low-volume peritoneal disease may be offered cytoreductive surgery with or without HIPEC at a high-volume centre, alongside systemic therapy. Evidence here is nuanced and the PRODIGE 7 trial has shaped practice toward careful patient selection rather than routine HIPEC.

Unlike rectal cancer, routine colon cancer is usually taken to surgery first and then to adjuvant chemotherapy. The reason is that the pelvic geometry that makes neoadjuvant radiotherapy and chemoradiation central to rectal cancer does not apply to the colon. There are specific exceptions: locally advanced T4b disease adherent to other organs, bulky nodal disease, or selected cT4 tumours where a short course of pre-operative chemotherapy may make surgery safer and cleaner (the FOxTROT trial explored this question). These are selected-patient decisions taken in a multidisciplinary meeting.

VICI Healthcare daycare delivers the medical part of the colon cancer pathway. We run adjuvant chemotherapy for Stage II high-risk and Stage III after surgery, first-line and later-line systemic therapy for Stage IV, immunotherapy infusions for MSI-high metastatic disease, and targeted-therapy infusions including bevacizumab, cetuximab, panitumumab, trastuzumab, and ramucirumab. Bone-marrow-supportive injections (G-CSF, erythropoietin) and blood transfusion support run alongside. Surgery, radiation, and HIPEC are referred to partner surgical and radiation oncology units; our role is to coordinate the referral, receive the post-operative patient back onto the adjuvant schedule, and track them during the intensive two-year follow-up window [10].

A typical chemotherapy day starts with a blood count and a review of side effects from the previous cycle. The doctor signs off, the pharmacy prepares the infusion, and a nurse sets up the port. A FOLFOX cycle is a four- to six-hour infusion in the chair, followed by a 46-hour take-home 5-FU pump that you return to us to disconnect. CAPOX is shorter in-chair because capecitabine goes home as tablets.

VICI Healthcare medical oncologists review your pathology, staging, molecular panel, and surgical plan before your first cycle. Every Stage III and Stage IV patient is discussed in our multidisciplinary review with surgical and radiation colleagues before treatment starts. A dedicated nurse navigator stays with you through every cycle. Profiles of our consulting medical oncologists are listed on the VICI Healthcare team page.

VICI Healthcare daycare centers deliver oxaliplatin-based adjuvant, targeted therapy infusions, and immunotherapy in a comfortable single-day setting close to home. Each centre has a prepared pharmacy, dedicated infusion chairs, an emergency crash station, and rapid escalation to a partner inpatient unit if required. Our flagship Chandigarh centre is operational, and additional VICI Healthcare units are opening across the NCR and metro cities.

• Three months vs six months of CAPOX: the IDEA collaboration lets us shorten adjuvant in lower-risk Stage III, reducing neuropathy without losing meaningful efficacy.
• Molecular-guided first-line in Stage IV: RAS/BRAF/MSI/HER2 testing now drives first-line choice, replacing the one-size-fits-all doublet of earlier decades.
• Immunotherapy in MSI-high metastatic disease: KEYNOTE-177 changed first-line treatment for MSI-high metastatic colorectal cancer from chemotherapy to checkpoint inhibition.
• HER2-directed therapy: trastuzumab combinations have opened a new line for a small but important subgroup.
• Complete mesocolic excision: improved surgical technique has raised nodal yield, which in turn sharpens the accuracy of staging and adjuvant decisions.

Pros: clear absolute reduction in recurrence risk for Stage III, especially N2 disease; short-course CAPOX is often tolerable; well-validated by decades of trial evidence.

Cons: oxaliplatin causes peripheral neuropathy that may persist; nausea, diarrhoea, and fatigue are common; the absolute benefit is smaller for low-risk Stage II and for older, frailer patients with competing comorbidities. We walk through this decision with you in clinic before you sign consent.

• Peripheral neuropathy (oxaliplatin): we monitor each cycle, adjust dose early, and pause oxaliplatin before neuropathy becomes disabling. Cold-avoidance advice and duloxetine are offered.
• Hand-foot syndrome (capecitabine): urea-based creams, dose reduction, and in some cases a short break.
• Diarrhoea (5-FU, capecitabine, irinotecan): loperamide at home, hydration, and rapid review for any fever.
• Neutropenia: monitored before every cycle, G-CSF support if needed.
• Infusion reactions (cetuximab, oxaliplatin): premedication, slow first infusions, rapid rescue available.
• Skin rash (anti-EGFR antibodies): pre-emptive doxycycline, steroid cream, gentle skincare.

“I was terrified of the word Stage III. The VICI Healthcare team sat down with my pathology report and explained exactly why I needed adjuvant chemo, how long it would last, and what to expect. Every cycle ran on time.” — patient, age 58, Chandigarh.

“The daycare was calm and clean. The nurses caught my low counts early and pushed me through the full course. Six months later my CEA is normal and my scans are clean.” — patient, age 47, Mohali.

Video stories from VICI Healthcare colon cancer survivors are being compiled for this page. If you would like to share your own experience, please contact our patient relations team.

Reviewed by the VICI Healthcare Medical Oncology Team. Last medical review: 8 April 2026. See the reviewer profile.

This page is educational. It is not a substitute for an individual consultation with a qualified medical oncologist. Treatment choices depend on your pathology, imaging, molecular profile, fitness, and personal preferences. Please speak with a VICI Healthcare oncologist before starting, stopping, or changing any cancer treatment. Reviewed by the VICI Healthcare Medical Oncology Team on 8 April 2026.